Literature DB >> 31382210

Effects of transcutaneous electrical nervous stimulation (TENS) associated with vocal therapy on musculoskeletal pain of women with behavioral dysphonia: A randomized, placebo-controlled double-blind clinical trial.

Larissa Thais Donalonso Siqueira1, Vanessa Veis Ribeiro2, Pamela Aparecida Medeiros Moreira3, Alcione Ghedini Brasolotto4, Rinaldo Roberto de Jesus Guirro5, Kelly Cristina Alves Silverio6.   

Abstract

Recently, electrical stimulation in vocal rehabilitation has been the subject of studies. This treatment has shown promising results regarding the decrease of vocal/laryngeal symptoms, pain and the improvement of vocal tension. In addition to decreasing pain symptoms, TENS treatments may lead to muscle relaxation. There is no data on the effects of this resource as a vocal therapy in women with behavioral dysphonia. Research in this area may provide evidence to assist the clinical decision related to the treatment of women with complaints of behavioral dysphonia and musculoskeletal pain.
OBJECTIVE: To verify the effects of low-frequency TENS in association with vocal therapy on musculoskeletal pain in women with behavioral dysphonia.
METHODS: Participants included 27 women with vocal nodules randomized into two groups. The experimental group (EG) - 13 women received 12 sessions of TENS (pulse of 200 μs, frequency at 10 Hz, in motor threshold) with electrodes placed bilaterally on the trapezius muscle and submandibular area for 20 min followed by 30 min of vocal therapy, and the control group (CG) - 14 women received 12 sessions of 20 min of a placebo TENS followed by 30 min of vocal therapy. We investigated the frequency and intensity of the musculoskeletal pain in several body regions, as well as the intensity of pain at rest and in the application of pressure with an algometer applied to the descending fibers of the trapezius muscle. The pressure-pain threshold (PPT) was also investigated. All evaluations occurred before, immediately after, and at one and three months after treatment in both groups.
RESULTS: We observed a reduction in the frequency of pain in the larynx after treatment of both groups, but only the EG showed a decrease in pain intensity in this region. It was verified with an algometer to the trapezius muscle that the electrical stimulation associated with the vocal therapy decreased the intensity of pain during the application of pressure and increased the PPT. There were no significant differences with regard to variables investigated in the comparison between the interventions. On the other hand, there was decreased pain in the trapezius muscle for the EG in comparison to the pre- and post-intervention.
CONCLUSION: The vocal therapyprogram reduced the frequency and intensity of the musculoskeletal pain in the regions proximal to the larynx of women with behavioral dysphonia. In addition, TENS followed by vocal therapy increased the threshold of sensitivity to muscular pain in the trapezius, demonstrating that it is a good resource to use in conjunction with traditional vocal therapy in cases of behavioral dysphonia associated with pain and muscle tension.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Transcutaneous electric nerve stimulation; Voice; Voice training

Year:  2019        PMID: 31382210     DOI: 10.1016/j.jcomdis.2019.105923

Source DB:  PubMed          Journal:  J Commun Disord        ISSN: 0021-9924            Impact factor:   2.288


  2 in total

Review 1.  Characterising the Features of 381 Clinical Studies Evaluating Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Relief: A Secondary Analysis of the Meta-TENS Study to Improve Future Research.

Authors:  Mark I Johnson; Carole A Paley; Priscilla G Wittkopf; Matthew R Mulvey; Gareth Jones
Journal:  Medicina (Kaunas)       Date:  2022-06-14       Impact factor: 2.948

Review 2.  Effects of electrical stimulation on skin surface.

Authors:  Xinkai Xu; Han Zhang; Yan Yan; Jianru Wang; Liang Guo
Journal:  Acta Mech Sin       Date:  2021-02-06       Impact factor: 2.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.